Start exploring your own markets for free

🚀 Try for Free

AI Therapeutics

Light Search completed

Invite

Radar Tracking

Subspaces (4)

Drug Discovery Optimization

Biomarker Identification

Genomic Data Analysis

Drug Repurposing

Pending to review

Not sure yet

Interested

Not interested

Download list

Showing 104 results

Company	Fit assessment	Description	Subspaces	Tags	HQ Location	Founding Date	Employees	Total Funding Raised	Last Funding Event	Received on
Pure Functionals	Pure Functionals effectively leverages machine learning and genomic data analysis to enhance clinical decision-making and expand therapeutic options.	Developer of a genomic-based artificial intelligence platform designed to offer bespoke health alternatives, as well as provide insight and precision health analysis for benefit of clinical trials. The company's platform offers insights that will be used to initiate clinical trials as well as consult with existing clinical trials in order to improve efficiency and effectiveness, enabling patients to enhance personalized care by improving clinical decision making.	Genomic Data Analysis	Light Search	Amsterdam (Netherlands)	2020	1 - 10		Seed, January 1, 2023	Oct 14, 2024
Biodesix	Biodesix leverages machine learning and multi-technology approaches to enhance therapeutic options and identify biomarkers, driving personalized medicine in lung cancer diagnostics.	Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.	Biomarker Identification	Light Search	United States	2005	201 - 500	$917.77M	Post-IPO Equity, $55.00M, April 5, 2024	Oct 14, 2024
Biotx.ai	Biotx.ai leverages machine learning for pattern discovery and therapeutic expansion, while also focusing on biomarker identification for precision medicine.	Developer of a drug discovery platform designed to identify significant patterns for developing novel diagnostics and therapies. The company's platform effectively monitors individual responses like artificial neural networks to stratify patients in clinical studies and develop new drugs, enabling physicians to overcome unmet medical needs.	Biomarker Identification	Light Search	Germany	2017	1 - 10		Convertible Note, April 5, 2023	Oct 14, 2024
Innoplexus	INNOPLEXUS effectively leverages machine learning to discover patterns and expand therapeutics, while also focusing on biomarker identification for personalized medicine.	Developer of advanced artificial intelligence and blockchain technology platform designed to support all stages of drug development from pipeline to market. The company's platform identifies and extracts structured and unstructured life science data by scanning the World Wide Web and merges it with enterprise and third-party data in an ongoing, real-time process, enabling life sciences organizations to generate actionable insights across pre-clinical, clinical, regulatory and commercial stages of drug development using data analytics.	Biomarker Identification	Light Search	Eschborn (Germany)	2011	201 - 500		Series C, April 24, 2019	Oct 14, 2024
Nashville Biosciences	NashBio effectively leverages machine learning and pattern discovery to advance the development of personalized therapeutics and diagnostics.	Operator of a clinical big data, genomics and medical imaging company intended to accelerate the R&D activity of partners in the biopharmaceutical, diagnostics, and AI industries. The company harnesses extensive genomic and bioinformatics resources for drug and diagnostics discovery and development, from a comprehensive genetic database linked to de-identified medical records of longitudinal clinical data to provide clinical insight, resources, and expertise to a wide range of R&D challenges.	Genomic Data Analysis	Light Search	Nashville (United States)	2018	17		NA	Oct 14, 2024
ATOM Accelerating Therapeutics for Opportunities in Medicine	ATOM leverages machine learning and data-driven modeling to enhance drug discovery, focusing on developing new therapeutics and optimizing the drug design process.	The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission accelerating the development of more effective therapies for patients. Our goal is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient-centric model. We are integrating high performance computing, diverse biological data, and emerging biotechnologies to create a new pre-competitive platform for drug discovery.	Drug Discovery Optimization	Light Search	United States	2017	11 - 50		NA	Oct 14, 2024
Cobiomic Bioscience	Cobiomic Bioscience leverages machine learning and bioinformatics to enhance biomarker identification and expand therapeutic options, ultimately improving patient care.	Developer of biomarker identification platform intended for improving the quality of life for patients. The company's technology helps in providing proteomics analysis and combines blood analysis, clinical information and bioinformatics, enabling patients to get the right treatment at the right time.	Biomarker Identification	Light Search	Spain	2022	1 - 10		NA	Oct 14, 2024
Pharmaeconomica	Pharmaeconomica effectively leverages machine learning and AI to discover new drug candidates, adapt to various therapeutic areas, and optimize the drug discovery process.	Operator of an AI-enhanced physics-based drug discovery company headquartered in Oostende, Belgium. The company discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates, and combines artificial intelligence, computational chemistry, and peptide science to accelerate therapeutic compound discovery, streamline hit identification, and optimize leads.	Drug Discovery Optimization	Light Search	Belgium	2012	1 - 10		NA	Oct 14, 2024
Owkin	Owkin effectively utilizes machine learning to discover patterns, expand therapeutics, and identify biomarkers, enhancing personalized medicine.	Developer of machine learning tools designed to augment medical and biological research. The company's tool integrates biomedical images, genomics, and clinical data to discover mechanisms and biomarkers associated with diseases and treatment outcomes and build models that are as interpretable as possible, enabling researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process and identify the best drug for the right patient to improve treatment outcomes.	Biomarker Identification	Light Search	New York (United States)	2016	201 - 500	$304.10M	Series B, $50.00M, June 8, 2022	Oct 14, 2024
Frontier Medicines	Frontier Medicines effectively leverages machine learning to discover new patterns in protein interactions and expand therapeutic options, optimizing the drug discovery process.	Developer of a chemoproteomics platform designed to accelerate the development of medicines. The company's platform integrates computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling healthcare professionals to provide medicines to patients that redefine the course of debilitating diseases.	Drug Discovery Optimization	Light Search	United States	2018	51 - 200	$255.50M	Series C, $20.00M, June 25, 2024	Oct 14, 2024